Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiichi Torimoto

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Rheumatology (Oxford, England)|November 3, 2021
An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosusMaiko Hajime Sumikawa, Shigeru Iwata, Mingzeng Zhang, et al.
Rheumatology (Oxford, England)|March 11, 2021
Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritisShigeru Iwata, Mingzeng Zhang, Maiko Hajime, et al.
Diabetes & Metabolism|April 28, 2023
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)Atsushi Tanaka, Yosuke Okada, Keiichi Torimoto, et al.
American Journal of Physiology. Cell Physiology|November 24, 2021
Glucose consumption of vascular cell types in culture: toward optimization of experimental conditionsKeiichi Torimoto, Keisuke Okuno, Ryohei Kuroda, et al.
Cardiovascular Diabetology|January 5, 2021
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trialNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 6, 2021
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes MellitusNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology|July 11, 2020
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative studyNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Kidney International Reports|May 25, 2026
Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKDAtsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, et al.
Cardiovascular Diabetology|December 5, 2025
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)Atsushi Tanaka, Muthiah Vaduganathan, Takumi Imai, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Rheumatology (Oxford, England)|November 3, 2021
An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosusMaiko Hajime Sumikawa, Shigeru Iwata, Mingzeng Zhang, et al.
Rheumatology (Oxford, England)|March 11, 2021
Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritisShigeru Iwata, Mingzeng Zhang, Maiko Hajime, et al.
Diabetes & Metabolism|April 28, 2023
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)Atsushi Tanaka, Yosuke Okada, Keiichi Torimoto, et al.
American Journal of Physiology. Cell Physiology|November 24, 2021
Glucose consumption of vascular cell types in culture: toward optimization of experimental conditionsKeiichi Torimoto, Keisuke Okuno, Ryohei Kuroda, et al.
Cardiovascular Diabetology|January 5, 2021
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trialNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 6, 2021
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes MellitusNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Cardiovascular Diabetology|July 11, 2020
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative studyNaoto Katakami, Tomoya Mita, Hidenori Yoshii, et al.
Kidney International Reports|May 25, 2026
Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKDAtsushi Tanaka, Takumi Imai, Muthiah Vaduganathan, et al.
Cardiovascular Diabetology|December 5, 2025
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)Atsushi Tanaka, Muthiah Vaduganathan, Takumi Imai, et al.
Pageof 8